U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Formulation for peptide release

Patent 5925619 Issued on July 20, 1999. Estimated Expiration Date: Icon_subject December 19, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

3917825

Sustained release formulations of water soluble peptides Patent #: 5538739
Issued on: 07/23/1996
Inventor: Bodmer, et al.

Inventors

Assignee

Application

No. 981285 filed on 12/19/1997

US Classes:

514/15, 9 to 11 peptide repeating units in known peptide chain424/422, Implant or insert424/423, Surgical implant or material424/425, Diffusion barrier is matrix424/426, Errodable, resorbable, or dissolving514/3, Insulin or derivative514/8, Glycoprotein (carbohydrate containing)514/12, 25 or more peptide repeating units in known peptide chain structure514/13, 16 to 24 peptide repeating units in known peptide chain514/1412 to 15 peptide repeating units in known peptide chain

Examiners

Primary: Moezie, F. T.

Attorney, Agent or Firm

Foreign Patent References

  • 37929/78 AU. 01/19/1980
  • 302582 EP. 02/19/1989
  • 2052258 GB. 01/19/1981
  • 92/18107 WO. 10/19/1992
  • 93/15722 WO. 08/19/1993

International Classes

A61D 019/00
A61D 007/00

Foreign Application Priority Data

1995-06-20 AU

Abstract

A pharmaceutical or veterinary formulation comprising deslorelin and an excipient is provided which releases in vitro deslorelin into phosphate buffered saline at 370° C. at a rate of about 2-80 μg/day for at least 200 days. The formulation may be used for prevention of reproductive function, particularly in dogs and cats, and for the treatment particularly in humans, of prostate and breast cancer and other diseases and conditions where suppression of testosterone or estradiol levels is beneficial.

Other References

  • Journal of Clinical Endocrinolgy and Metabolism, 1991 by The Endocrine Society; Effects of Pitsuitary-Testicular Axis Suppression in Utero and During the Early Neonatal Period With Long-Acting Luteinizing Hormone-Releasing Hormone Analog on Gential Development, Somatic Growth, and Bone Density in Male Cynomolgus Monkeys in the First 6 Months of Life, By Linda Liu et al, pp. 1038-1043
  • British Poultry Science, vol. 33, No. 3 1992, (Edinburgh, Scotland), A.J. Tilbrook et al, "Short-term reduction in Egg Production in Laying Hens Treated With an Agonist of GnRH". pp. 621-638
  • Journal of Animal Science, vol. 74, No. 1, 1996 (Champaign, Illinois, U.S.A.), D'Occhio, M.J. et al "Controlled Reversible Suppression of Beef Heifers and Cows using Agonists of Gonadotrophin-Releasing Hormone", pp. 218-225, see especially p. 233
  • Biology of Reproduction, vol. 42, No. 1, 1996(champaign, Illinoise, U.S.A.), D'Occhio, M.J. et al "Characteristics Hormones (LH) and Testosterone Secretion, Pituitary Responses to LH-Releasing Hormone (LHRH), and Reproductive Function in Young Bulls Receiving the LHRH Agonist Deslorelin: Effect of castration on LH responses to LRRH" pp. 45-52, See especially p. 46
  • Stedman's Medical Dictionary, 25th Ed., Williams & Wilkins, Baltimore, USA p. 147
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
PatentsPlus: add to cart
PatentsPlus: add to cartIntelligent turbocharged patent PDFs with marked up images
$16.95more info
 
Sign InRegister
Username  
Password   
forgot password?